Lysine-rich cell penetrating peptides

By designing arginine-rich lysine-rich cell penetration peptide, the problem of difficulty in isolating the efficacy and toxicity of existing CPPs in the treatment of neuromuscular diseases is solved, and a more efficient and safe intracellular delivery effect is achieved.

CN118973596APending Publication Date: 2024-11-15OXFORD UNIVERSITY INNOVATION LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380032884.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-08
Filing Date
2023-04-05
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing cell penetration peptides (CPPs) have problems in the treatment of neuromuscular diseases, especially the problems of ineffectiveness or excessive toxicity in the treatment of human diseases, and There are limited research on different amino acid substitutions.

Method used

A peptide with a total length of 40 amino acid residues or less, comprising at least two cationic domains and at least one hydrophobic domain, and without arginine residues, is designed, and arginine is replaced by lysine. to improve cell penetration and reduce toxicity.

Benefits of technology

It has achieved a significant reduction in the number of nuclear lesions and significantly reduced toxicity without reducing cell viability, providing a more effective treatment window and safer clinical advantage.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118973596A_ABST
    Figure CN118973596A_ABST
Patent Text Reader

Abstract

The present invention relates to peptides, in particular cell penetrating peptides, and conjugates of such cell penetrating peptides with therapeutic molecules wherein the peptide comprises at least two cationic domains, each cationic domain comprising a plurality of lysine residues, and wherein the peptide does not comprise arginine residues. The invention also relates to the use of such peptides or conjugates in methods of treatment or as medicaments, in particular in the treatment of genetic disorders and in particular neuromuscular diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to peptides, in particular cell penetrating peptides, and to conjugates of such cell penetrating peptides with therapeutic molecules. The present invention also relates to the use of such peptides or conjugates in methods of treatment or as medicaments, in particular in the treatment of genetic disorders and especially neuromuscular diseases. Background Art

[0002] Nucleic acid drugs are genomic medicines that have the potential to transform human healthcare. Research suggests that such therapies may find application in a wide range of disease areas, including neuromuscular diseases. For example, the application of antisense oligonucleotide-based approaches to modulate pre-mRNA splicing in the neuromuscular disease Duchenne muscular dystrophy (DMD) has placed these monogenic disorders at the forefront of precision medicine development.

[0003] While progress has been made in the field of antisense therapies for treating diseases caused by splicing errors, problems with delivering such therapeutics to the tissues that need them have hampered success. In September 2016, the U.S. Food and Drug Administration (FDA) granted accelerated approval for "eteplirsen," a single-stranded oligonucleotide used to modulate splicing of exon 51, the region that causes DMD. However, levels of dystrophin restoration were disappointing, with only about 1% of normal dystrophin levels. Comparisons with the allelic disorder Becker muscular dystrophy and experiments in mdx mice suggest that homogenous sarcolemmal dystrophin expression of at least about 15% of wild type is required to protect muscles from exercise-induced damage. The reason for the poor effect is presumed to be due to poor delivery.

[0004] Therefore, there is a strong and urgent need to improve the delivery of antisense oligonucleotides in order to provide more effective therapies for devastating genetic diseases such as DMD.

[0005] The use of viruses as delivery vehicles has been proposed, but their use is limited due to the immunotoxicity and potential carcinogenicity of viral coat proteins. Alternatively, a variety of non-viral delivery vectors have been developed, of which peptides have been shown to be the most promising due to their small size, targeting specificity, and ability to deliver large biological cargoes across capillaries. The ability of a variety of peptides to penetrate cells alone or with biological cargo has been reported.

[0006] For many years, cell-penetrating peptides (CPPs) have been conjugated to single-stranded oligonucleotides, especially neutrally charged phosphorodiamidate morpholino oligomers (PMOs) and peptide nucleic acids (PNAs), to enhance the cellular delivery of such therapeutics by efficiently carrying them across cell membranes to their pre-mRNA target sites in the nucleus. It has been shown that PMO therapeutics conjugated to certain arginine-rich CPPs, termed P-PMOs or peptide-PMOs, can enhance dystrophin production in skeletal muscle following systemic administration in the mdx mouse model of DMD.

[0007] Specifically, a group of CPPs were developed that have two arginine-rich sequences separated by a short hydrophobic sequence in the middle. These peptides were designed to improve serum stability while maintaining relatively high levels of exon skipping, which was initially achieved by attaching them to PNA therapeutics. Other derivatives of these peptides were designed as conjugates of PMOs, which were shown to result in systemic skeletal muscle dystrophin production after systemic administration in mice. Although these CPPs are effective in delivery, their therapeutic applications are limited by their associated toxicity.

[0008] Alternative cell penetrating peptides with only a single arginine-rich domain, such as R6Gly, have also been generated. These CPPs have been used to produce peptide conjugates with reduced toxicity, but R6Gly conjugates showed low efficacy compared to the arginine-rich dual-domain CPPs.

[0009] Therefore, currently available CPPs have not been shown to be suitable for use in the treatment of diseases such as DMD in humans. They have been shown to be either ineffective or too toxic.

[0010] The challenge in the field of cell penetrating peptide technology is to uncouple efficacy and toxicity. Studies on CPPs to date have shown that peptides containing a large number of arginine residues are key to cell penetrating ability, and a large body of evidence teaches that arginine is essential. Although a large number of arginine residues increases the toxicity of CPPs, there are few studies on peptides that replace arginine with different amino acids. A solution to toxicity may involve replacing arginine with other essential amino acids, but studies on this have concluded that such alternative peptides are ineffective.

[0011] The inventors of the present application have now identified, synthesized and tested a number of improved CPPs which may at least address this problem. Summary of the invention

[0012] According to a first aspect of the present invention, there is provided a peptide having a total length of 40 amino acid residues or less, the peptide comprising at least two cationic domains and at least one hydrophobic domain, wherein the at least two cationic domains each comprise a plurality of lysine residues, and wherein the peptide does not contain arginine residues.

[0013] According to a second aspect of the present invention, there is provided a conjugate comprising the peptide according to the first aspect covalently linked to a therapeutic molecule.

[0014] According to a third aspect, there is provided a pharmaceutical composition comprising the conjugate according to the second aspect.

[0015] According to a fourth aspect, there is provided a conjugate according to the second aspect or a pharmaceutical composition according to the third aspect for use as a medicament.

[0016] According to a fifth aspect, a conjugate according to the second aspect or a pharmaceutical composition according to the third aspect is provided for use in treating a disease of the neuromuscular system or the musculoskeletal system, preferably a genetic disease of the neuromuscular system or the musculoskeletal system, preferably an inherited genetic disease of the neuromuscular system or the musculoskeletal system.

[0017] Therefore, it will be appreciated that it would be particularly advantageous to deliver the conjugate or pharmaceutical composition according to the invention directly to the affected tissue. The inventors have found that the conjugates according to the invention exhibit positive biodistribution and delivery to specific tissues (e.g. bone and cardiac tissue) (as shown in the examples).

[0018] The inventors unexpectedly discovered that arginine can be substituted with lysine in cell penetrating peptides and still achieve good cell penetration with reduced toxicity. In fact, the inventors found that CPPs that do not contain arginine residues but contain lysine residues have greatly reduced toxicity. It was previously believed that lysine interacted less efficiently with cell surface proteoglycans because it is less basic than arginine. Some past studies have shown that replacing arginine with lysine residues reduces the uptake of conjugates containing CPPs and further reduces the endosomal escape of the conjugates in cells, resulting in poor activity. It has been reported that in some cases, a minimum number of arginine residues are required to induce the escape of CPPs from endosomes into the cytosol so that it can transport its therapeutic payload to targets that are usually located in the nucleus. The inventors have demonstrated that lysine-rich CPPs can actually serve as effective delivery agents in conjugates with a wide therapeutic window and do not require the presence of arginine. The results presented herein show that changing arginine to lysine in CPPs widens the difference between median activity and toxicity compared to previous CPPs.

[0019] Advantageously, the inventors have demonstrated that the conjugates according to the invention are able to reduce the number of nuclear foci in cells at concentrations that do not result in a decrease in cell viability. This is in contrast to control cells that induce significant cell death at similar concentrations (as described in the Examples section).

[0020] Suitably, the conjugates according to the invention may reduce nuclear foci in cells by more than 30%, more than 35%, more than 40%, more than 45%, more than 50%, more than 55%, more than 60%, more than 65%, more than 70%, more than 75%, more than 80%, more than 85%, more than 90%, more than 95%, more than 96%, more than 97%, more than 98%, more than 99%, or by 100%.

[0021] The inventors have also found that the use of conjugates according to the invention can significantly reduce toxicity compared to control peptides (as shown in the Examples section). It will be appreciated that reducing toxicity caused by conjugates used for therapeutic purposes provides significant clinical advantages.

[0022] The present invention includes any combination of the described aspects and features, unless such a combination is expressly impermissible or explicitly avoided.

[0023] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

[0024] "X" is used throughout to denote any form of the artificial, synthetically prepared amino acid aminocaproic acid, preferably 6-aminocaproic acid.

[0025] "B" is used throughout to represent the natural but non-genetically encoded amino acid beta-alanine.

[0026] Acetylation of the relevant peptide is indicated throughout by “Ac”.

[0027] Additional capital letters are used throughout to indicate amino acid residues encoded by the relevant gene according to the generally accepted alphabetical amino acid code.

[0028] Cationic domain

[0029] The present invention relates to short cell penetrating peptides with a specific structure, in which at least two lysine-rich cationic domains are present.

[0030] "Cationic" as referred to herein refers to an amino acid or domain of amino acids having an overall positive charge at physiological pH.

[0031] Suitably, the peptide comprises at most 4 cationic domains, at most 3 cationic domains.

[0032] Suitably, the peptide comprises two cationic domains. Suitably, the peptide comprises a first cationic domain and a second cationic domain.

[0033] As defined above, the peptide comprises two or more cationic domains, each cationic domain having a length of at least 4 amino acid residues.

[0034] Suitably, each cationic domain is from 4 to 12 amino acid residues in length, suitably from 4 to 9 amino acid residues in length.

[0035] Suitably, each cationic domain is 4, 5, 6, 7, 8 or 9 amino acid residues in length.

[0036] Suitably, each cationic domain is of similar length, suitably, each cationic domain is of the same length.

[0037] Suitably, each cationic domain comprises cationic amino acids, and may also comprise polar and / or non-polar amino acids.

[0038] The non-polar amino acids may be selected from the group consisting of: alanine, beta-alanine, proline, glycine, cysteine, valine, leucine, isoleucine, methionine, tryptophan, phenylalanine, aminocaproic acid. Suitably, the non-polar amino acids have no charge.

[0039] The polar amino acid may be selected from: serine, asparagine, hydroxyproline, histidine, threonine, tyrosine, glutamine. Suitably, the polar amino acid selected does not have a negative charge.

[0040] The cationic amino acid may be selected from: lysine or histidine. Suitably, the cationic amino acid has a positive charge at physiological pH.

[0041] Suitably, each cationic domain comprises no anionic or negatively charged amino acid residues.

[0042] Suitably, each cationic domain does not comprise any arginine residues.

[0043] Suitably, each cationic domain comprises lysine, β-alanine and / or aminocaproic acid residues.

[0044] Suitably, each cationic domain consists of lysine, β-alanine and / or aminocaproic acid residues.

[0045] Suitably, each cationic domain comprises at least 40%, at least 45%, at least 50% cationic amino acids.

[0046] Suitably, each cationic domain comprises a majority of cationic amino acids. Suitably, each cationic domain comprises at least 40%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% of cationic amino acids.

[0047] Suitably, the isoelectric point (pi) of each cationic domain is at least 7.5, at least 8.0, at least 8.5, at least 9.0, at least 9.5, at least 10.0, at least 10.5, at least 11.0, at least 11.5, at least 12.0.

[0048] Suitably, each cationic domain has an isoelectric point (pi) of at least 10.0.

[0049] Suitably, each cationic domain has an isoelectric point (pi) of from 10.0 to 13.0.

[0050] In one embodiment, the isoelectric point (pi) of each cationic domain is between 10.4 and 12.5.

[0051] Suitably, the isoelectric point of the cationic domain may be calculated at physiological pH by any suitable method available in the art. Suitably, by using IPC (www.isoelectric.org), a web-based algorithm developed by Lukasz Kozlowski, Biol Direct. 2016; 11:55. DOI: 10.1186 / s13062-016-0159-9.

[0052] Suitably, each cationic domain comprises at least 1 cationic amino acid, suitably, comprises 1-10 cationic amino acids. Suitably, each cationic domain comprises at least 2 cationic amino acids, suitably, comprises 2-10 cationic amino acids, suitably, comprises 2-6 cationic amino acids.

[0053] Suitably, the at least one cationic amino acid consists of lysine. Suitably, the at least one cationic amino acid contained in each cationic domain consists of lysine. Thus, suitably, all cationic amino acids in a given cationic domain are lysine.

[0054] Therefore, suitably, each cationic domain can be referred to as "rich in lysine", and any cationic domain appearing herein can be replaced by a lysine-rich domain. "Rich in lysine" means that at least 40% of the cationic domains are formed by the residues. Suitably, each cationic domain comprises most of the lysine residues. Suitably, each cationic domain comprises at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% of the lysine residues. Suitably, each cationic domain comprises at least 60%, at least 70%, at least 80%, at least 90% of the lysine residues.

[0055] Suitably, each cationic domain comprises at least 1 lysine residue, suitably 1-10 lysine residues. Suitably, each cationic domain comprises at least 2 lysine residues, suitably 2-10 lysine residues, suitably 2-6 lysine residues.

[0056] Suitably, each cationic domain comprises no more than 3 consecutive lysine residues, suitably no more than 2 consecutive lysine residues.

[0057] Suitably, each cationic domain may also comprise one or more β-alanine and / or aminocaproic acid residues.

[0058] Suitably, each cationic domain may comprise 1-2 β-alanine residues. Suitably, each cationic domain may comprise 1-2 aminocaproic acid residues.

[0059] Suitably, the peptide comprises at least two lysine-rich domains. Suitably, at least two lysine-rich cationic domains. Suitably, the peptide comprises two lysine-rich domains. Suitably, two lysine-rich cationic domains.

[0060] In one embodiment, the peptide comprises a first cationic domain comprising lysine, β-alanine, and aminocaproic acid residues; and a second cationic domain comprising lysine, β-alanine, and aminocaproic acid residues.

[0061] In one embodiment, the peptide comprises a first cationic domain consisting of lysine, β-alanine and aminocaproic acid residues; and a second cationic domain consisting of lysine, β-alanine and aminocaproic acid residues.

[0062] In one embodiment, the peptide comprises a first lysine-rich domain comprising lysine, β-alanine, and aminocaproic acid residues; and a second lysine-rich domain comprising lysine, β-alanine, and aminocaproic acid residues.

[0063] In one embodiment, the peptide comprises a first lysine-rich domain consisting of lysine, β-alanine and aminocaproic acid residues; and a second lysine-rich domain consisting of lysine, β-alanine and aminocaproic acid residues.

[0064] Suitably, the peptide comprises at least two cationic domains, and suitably, these cationic domains form the arms of the peptide. Suitably, the cationic domains are located at the N and C-terminal ends of the peptide. Suitably, the cationic domains can therefore be referred to as cationic arm domains.

[0065] In one embodiment, the peptide comprises two cationic domains, one of which is located at the N-terminus of the peptide, and one is located at the C-terminus of the peptide. Suitably, at either end of the peptide. Suitably, no other amino acids or domains are present at the N-terminus and C-terminus of the peptide, except other groups such as terminal modifications, joints and / or therapeutic molecules. For the avoidance of doubt, in addition to the "peptide" described and claimed herein, such other groups may also be present. Suitably, each cationic domain therefore forms the end of the peptide. Suitably, this does not exclude the presence of other linker groups as described herein.

[0066] Suitably, the peptide may comprise up to 4 cationic domains. Suitably, the peptide comprises two cationic domains. Suitably, the peptide comprises a first cationic domain and a second cationic domain.

[0067] In one embodiment, the peptide comprises two cationic domains, both of which are lysine-rich. Suitably, the peptide comprises a first lysine-rich domain and a second lysine-rich domain.

[0068] Suitably, the cationic domain comprises an amino acid unit selected from the group consisting of B, BB, BBB, X, XX, XXX, K, KK, KKK, BK, KB, BX, XB, XK, KX, BKB, BXB, KBK, XBX, KXK, XKX, BBK, BBX, XXB, XXK, KKB, KKX, KBB, XBB, KXX, BKK, XKK or any combination thereof.

[0069] Suitably, each cationic domain comprises any of the following sequences: KXKKBKK (SEQ ID NO.1), KXKKBKKXK (SEQ ID NO.2), KBKKBKK (SEQ ID NO.3), KBKKBK (SEQ ID NO.4), KBKK (SEQ ID NO.5), KXKBKXK (SEQ ID NO.6), KBKXK (SEQ ID NO.7), KBKBK (SEQ ID NO.8), and BKBK (SEQ ID NO.9).

[0070] Suitably, each cationic domain comprises one of the following sequences: KXKKBKK (SEQ ID NO.1), KXKKBKKXK (SEQ ID NO.2), KBKKBKK (SEQ ID NO.3), KBKKBK (SEQ ID NO.4), KBKK (SEQ ID NO.5), KXKBKXK (SEQ ID NO.6), KBKXK (SEQ ID NO.7), KBKBK (SEQ ID NO.8), and BKBK (SEQID NO.9).

[0071] Suitably, each cationic domain consists of any of the following sequences: KXKKBKK (SEQ ID NO.1), KXKKBKKXK (SEQ ID NO.2), KBKKBKK (SEQ ID NO.3), KBKKBK (SEQ ID NO.4), KBKK (SEQ ID NO.5), KXKBKXK (SEQ ID NO.6), KBKXK (SEQ ID NO.7), KBKBK (SEQ ID NO.8), and BKBK (SEQID NO.9).

[0072] Suitably, each cationic domain consists of one of the following sequences: KXKKBKK (SEQ ID NO.1), KXKKBKKXK (SEQ ID NO.2), KBKKBKK (SEQ ID NO.3), KBKKBK (SEQ ID NO.4), KBKK (SEQ ID NO.5), KXKBKXK (SEQ ID NO.6), KBKXK (SEQ ID NO.7), KBKBK (SEQ ID NO.8), and BKBK (SEQID NO.9).

[0073] Suitably, the first cationic domain comprises any of the following sequences: KXKKBKK (SEQ ID NO.1), KXKKBKKXK (SEQ ID NO.2), KBKKBKK (SEQ ID NO.3), KBKKBK (SEQ ID NO.4), and KBKK (SEQID NO.5). Suitably, the first cationic domain consists of any of the following sequences: KXKKBKK (SEQ ID NO.1), KXKKBKKXK (SEQ ID NO.2), KBKKBKK (SEQ ID NO.3), KBKKBK (SEQ ID NO.4), and KBKK (SEQID NO.5).

[0074] Suitably, the first cationic domain comprises one of the following sequences: KXKKBKK (SEQ ID NO.1), KXKKBKKXK (SEQ ID NO.2), KBKKBKK (SEQ ID NO.3), KBKKBK (SEQ ID NO.4), and KBKK (SEQID NO.5). Suitably, the first cationic domain consists of any of the following sequences: KXKKBKK (SEQ ID NO.1), KXKKBKKXK (SEQ ID NO.2), KBKKBKK (SEQ ID NO.3), KBKKBK (SEQ ID NO.4), and KBKK (SEQID NO.5).

[0075] Suitably, the second cationic domain comprises any of the following sequences: KXKBKXK (SEQ ID NO.6), KBKXK (SEQ ID NO.7), KBKBK (SEQ ID NO.8), and BKBK (SEQ ID NO.9). Suitably, the second cationic domain consists of any of the following sequences: KXKBKXK (SEQ ID NO.6), KBKXK (SEQ ID NO.7), KBKBK (SEQ ID NO.8), and BKBK (SEQ ID NO.9).

[0076] Suitably, the second cationic domain consists of one of the following sequences: KXKBKXK (SEQ ID NO.6), KBKXK (SEQ ID NO.7), KBKBK (SEQ ID NO.8), and BKBK (SEQ ID NO.9). Suitably, the second cationic domain consists of any of the following sequences: KXKBKXK (SEQ ID NO.6), KBKXK (SEQ ID NO.7), KBKBK (SEQ ID NO.8), and BKBK (SEQ ID NO.9).

[0077] Suitably, each cationic domain in the peptide may be the same or different. Suitably, each cationic domain in the peptide is different.

[0078] Hydrophobic domain

[0079] The present invention relates to short cell penetrating peptides with a specific structure, wherein at least one hydrophobic domain is present.

[0080] The "hydrophobicity" referred to herein refers to an amino acid or a domain of amino acids having the ability to repel water or not mix with water.

[0081] Suitably, the peptide comprises at most 3 hydrophobic domains, at most 2 hydrophobic domains.

[0082] Suitably, the peptide comprises one hydrophobic domain.

[0083] As defined above, the peptide comprises one or more hydrophobic domains, each hydrophobic domain having a length of at least 3 amino acid residues.

[0084] Suitably, each hydrophobic domain is 3-6 amino acids in length. Suitably, each hydrophobic domain is 5 amino acids in length.

[0085] Suitably, each hydrophobic domain may comprise non-polar, polar and hydrophobic amino acid residues.

[0086] The hydrophobic amino acid residue may be selected from the group consisting of alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, methionine and tryptophan.

[0087] The non-polar amino acid residues may be selected from the group consisting of: proline, glycine, cysteine, alanine, valine, leucine, isoleucine, tryptophan, phenylalanine, and methionine.

[0088] The polar amino acid residue may be selected from the group consisting of: serine, asparagine, hydroxyproline, histidine, arginine, threonine, tyrosine, glutamine.

[0089] Suitably, the hydrophobic domain comprises no hydrophilic amino acid residues.

[0090] Suitably, each hydrophobic domain comprises a majority of hydrophobic amino acid residues. Suitably, each hydrophobic domain comprises at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, 100% hydrophobic amino acids. Suitably, each hydrophobic domain consists of hydrophobic amino acid residues.

[0091] Suitably, each hydrophobic domain comprises a hydrophobicity measurement of at least 0.3, at least 0.4, at least 0.5, at least 0.6, at least 0.7, at least 0.8, at least 0.8, at least 1.0, at least 1.1, at least 1.2, at least 1.3 on the hydrophobicity scale.

[0092] Suitably, each hydrophobic domain comprises a hydrophobicity measurement of at least 0.3, at least 0.35, at least 0.4, at least 0.45 on the hydrophobicity scale.

[0093] Suitably, each hydrophobic domain comprises a hydrophobicity measurement of at least 1.2, at least 1.25, at least 1.3, at least 1.35 on the hydrophobicity scale.

[0094] Suitably, each hydrophobic domain comprises a hydrophobicity measurement of between 0.4 and 1.4 on the hydrophobicity scale.

[0095] In one embodiment, each hydrophobic domain comprises a hydrophobicity measurement of 0.45 to 0.48 on the hydrophobicity scale.

[0096] In one embodiment, each hydrophobic domain comprises a hydrophobicity measurement of 1.27 to 1.39 on the hydrophobicity scale.

[0097] Suitably, hydrophobicity is measured according to White and Wimley: WC Wimley and SH White, "Experimentally determined hydrophobicity scale for proteins at membrane interfaces" Nature Struct Biol 3:842 (1996).

[0098] Suitably, each hydrophobic domain comprises at least 3, at least 4 hydrophobic amino acid residues.

[0099] Suitably, each hydrophobic domain comprises phenylalanine, leucine, isoleucine, tyrosine, tryptophan, arginine, proline and glutamine residues. Suitably, each hydrophobic domain consists of phenylalanine, leucine, isoleucine, tyrosine, tryptophan, arginine, proline and / or glutamine residues.

[0100] In one embodiment, each hydrophobic domain consists of phenylalanine, leucine, isoleucine, tyrosine, arginine and / or glutamine residues.

[0101] Suitably, the peptide comprises a hydrophobic domain. Suitably, the or each hydrophobic domain is located at the center of the peptide. Suitably, the hydrophobic domain may therefore be referred to as a core hydrophobic domain. Suitably, the or each hydrophobic core domain is flanked by arm domains on either side. Suitably, the arm domain may comprise one or more cationic domains and one or more other hydrophobic domains. Suitably, each arm domain comprises a cationic domain.

[0102] In one embodiment, the peptide comprises two arm domains flanking a hydrophobic core domain, wherein each arm domain comprises a cationic domain.

[0103] In one embodiment, the peptide consists of two cationic arm domains flanked by a hydrophobic core domain.

[0104] Suitably, the or each hydrophobic domain comprises one of the following sequences: YQFLI (SEQ ID NO.10), ILFQY (SEQ ID NO.11), YRLFI (SEQ ID NO.12), and FQILY (SEQ ID NO.13). Suitably, the or each hydrophobic domain consists of one of the following sequences: YQFLI (SEQ ID NO.10), ILFQY (SEQ ID NO.11), YRLFI (SEQ ID NO.12), and FQILY (SEQ ID NO.13). Suitably, the or each hydrophobic domain comprises one of the following sequences: YQFLI (SEQ ID NO.10), or FQILY (SEQ ID NO.11). Suitably, the or each hydrophobic domain consists of one of the following sequences: YQFLI (SEQ ID NO.10), or FQILY (SEQ ID NO.13).

[0105] Suitably, each hydrophobic domain in the peptide may have the same sequence or a different sequence.

[0106] Peptides

[0107] The present invention relates to short cell penetrating peptides for use in the delivery of therapeutic cargo molecules in the treatment of medical conditions.

[0108] The sequence of the peptide is a continuous single molecule, so the domains of the peptide are continuous. Suitably, the peptide comprises several domains arranged linearly between the N-terminus and the C-terminus. Suitably, the domains are selected from the above-mentioned cationic domains and hydrophobic domains. Suitably, the peptide consists of a cationic domain and a hydrophobic domain, wherein the domains are as defined above.

[0109] Each domain has the consensus sequence characteristics described in the relevant part above, but the exact sequence of each domain can be varied and modified. Therefore, each domain may have a series of sequences. The combination of each possible domain sequence produces a series of peptide structures, and each peptide structure forms a part of the present invention. The characteristics of the peptide structures are described as follows.

[0110] Suitably, a hydrophobic domain separates any two cationic domains. Suitably, each hydrophobic domain is flanked on either side by a cationic domain.

[0111] Suitably, no cationic domain is adjacent to another cationic domain.

[0112] In one embodiment, the peptide comprises a hydrophobic domain flanked by two cationic domains arranged as follows:

[0113] [Cationic domain]–[Hydrophobic domain]–[Cationic domain]

[0114] Thus, suitably, the hydrophobic domain may be referred to as a core domain and each cationic domain may be referred to as an arm domain. Suitably, the hydrophobic arm domains are flanked on either side by a cationic core domain.

[0115] In one embodiment, the peptide consists of two cationic domains and one hydrophobic domain. Suitably, wherein the peptide consists of the following structure:

[0116] [First cationic domain]–[Hydrophobic domain]–[Second cationic domain]

[0117] In one embodiment, the peptide consists of a hydrophobic core domain flanked by two cationic arm domains.

[0118] In one embodiment, the peptide comprises or consists of a hydrophobic domain, the hydrophobic domain comprising a sequence selected from the group consisting of YQFLI (SEQ ID NO.10), ILFQY (SEQ ID NO.11), YRLFI (SEQ ID NO.12), and FQILY (SEQ ID NO.13), which is flanked by two cationic domains, each of which comprises a sequence selected from the group consisting of KXKKBKK (SEQ ID NO.1), KXKKBKKXK (SEQ ID NO.2), KBKKBKK (SEQ ID NO.3), KBKKBK (SEQ ID NO.4), KBKK (SEQ ID NO.5), KXKBKXK (SEQ IDNO.6), KBKXK (SEQ ID NO.7), KBKBK (SEQ ID NO.8), and BKBK (SEQ ID NO.9).

[0119] In one embodiment, the peptide comprises or consists of a hydrophobic domain, the hydrophobic domain comprising a sequence selected from the group consisting of YQFLI (SEQ ID NO.10), and FQILY (SEQ ID NO.13), which is flanked by two cationic domains, each of which comprises a sequence selected from the group consisting of KXKKBKK (SEQ ID NO.1), KXKKBKKXK (SEQ ID NO.2), KBKKBKK (SEQ ID NO.3), KBKKBK (SEQ ID NO.4), KBKK (SEQ ID NO.5), KXKBKXK (SEQ ID NO.6), KBKXK (SEQ ID NO.7), KBKBK (SEQ ID NO.8), and BKBK (SEQ ID NO.9).

[0120] In one embodiment, the peptide comprises or consists of a hydrophobic domain, the hydrophobic domain comprising a sequence selected from the group consisting of YQFLI (SEQ ID NO.10), ILFQY (SEQ ID NO.11), YRLFI (SEQ ID NO.12), and FQILY (SEQ ID NO.13), which is flanked by a first cationic domain, the first cationic domain comprising a sequence selected from the group consisting of KXKKBKK (SEQ ID NO.1), KXKKBKKXK (SEQ ID NO.2), KBKKBKK (SEQ ID NO.3), KBKKBK (SEQ ID NO.4), and KBKK (SEQ ID NO.5), and is flanked by a second cationic domain, the second cationic domain comprising a sequence selected from the group consisting of KXKBKXK (SEQ ID NO.6), KBKXK (SEQ ID NO.7), KBKBK (SEQ ID NO.8), and BKBK (SEQ ID NO.9).

[0121] In one embodiment, the peptide comprises or consists of a hydrophobic domain, the hydrophobic domain comprising a sequence selected from the group consisting of YQFLI (SEQ ID NO.10), and FQILY (SEQ ID NO.13), which is flanked by a first cationic domain, the first cationic domain comprising a sequence selected from the group consisting of KXKKBKK (SEQ ID NO.1), KXKKBKKXK (SEQ ID NO.2), KBKKBKK (SEQ ID NO.3), KBKKBK (SEQ ID NO.4), and KBKK (SEQ ID NO.5), and is flanked by a second cationic domain, the second cationic domain comprising a sequence selected from the group consisting of KXKBKXK (SEQ ID NO.6), KBKXK (SEQ ID NO.7), KBKBK (SEQ ID NO.8), and BKBK (SEQ ID NO.9).

[0122] In any such embodiments, other groups may be present, such as linkers, terminus modifications, and / or therapeutic molecules.

[0123] Suitably, the peptide is N-terminally modified.

[0124] Suitably, the peptide is N-acetylated, N-methylated, N-trifluoroacetylated, N-trifluoromethylsulfonylated or N-methylsulfonylated. Suitably, the peptide is N-acetylated.

[0125] Optionally, the N-terminus of the peptide may be unmodified.

[0126] In one embodiment, the peptide is N-acetylated.

[0127] Suitably, the peptide is C-terminally modified.

[0128] Suitably, the peptide comprises a C-terminal modification selected from the group consisting of: carboxyl-, thioacid-, aminooxy-, hydrazine-, thioester-, azide, strained alkyne, strained olefin, aldehyde-, thiol or haloacetyl groups.

[0129] Advantageously, the C-terminal modification provides a means for linking the peptide to a therapeutic molecule.

[0130] Thus, the C-terminal modification may comprise a linker, or vice versa. Suitably, the C-terminal modification may consist of a linker, or vice versa. Suitable linkers are described elsewhere herein.

[0131] Suitably, the peptide comprises a C-terminal carboxyl group.

[0132] Suitably, the C-terminal carboxyl group is provided by a cysteine, glycine or beta-alanine residue.

[0133] In one embodiment, the C-terminal carboxyl group is provided by a cysteine ​​residue.

[0134] Suitably, the C-terminal cysteine ​​residue is a linker.

[0135] Suitably, therefore, each cationic domain may further comprise an N or C terminal modification. Suitably, the cationic domain comprises a C-terminal modification at the C-terminus. Suitably, the cationic domain comprises an N-terminal modification at the N-terminus. Suitably, the cationic domain comprises a linker group at the C-terminus, and suitably, the cationic domain comprises a C-terminal β-alanine at the C-terminus. Suitably, the cationic domain is N-acetylated at the N-terminus.

[0136] The peptides of the present invention are defined as having a total length of 40 amino acid residues or less. Therefore, the peptides can be considered as oligopeptides.

[0137] Suitably, the peptide has a total length of 3-35 amino acid residues, suitably 5-30 amino acid residues in length, 10-25 amino acid residues in length, 13-23 amino acid residues in length, 15-20 amino acid residues in length.

[0138] Suitably, the total length of the peptide is at least 12, at least 13, at least 14, at least 15 amino acid residues.

[0139] Suitably, the peptide is less than 35 amino acid residues in length, less than 30 amino acid residues in length, less than 25 amino acid residues in length, less than 20 amino acid residues in length.

[0140] Suitably, the peptide is capable of penetrating cells. Thus, the peptide may be considered a cell penetrating peptide.

[0141] Suitably, the peptide is used to attach to a therapeutic molecule. Suitably, the peptide is used to transport a therapeutic molecule into a target cell. Suitably, the peptide is used to deliver a therapeutic molecule into a target cell. Thus, the peptide may be considered a carrier peptide.

[0142] Suitably, the peptide is capable of penetrating into cells and tissues, suitably into the nucleus of a cell. Suitably, into muscle tissue.

[0143] Suitably, the peptide may be selected from any of the following sequences:

[0144] KXKKBKK FQILY KBKXK(ERA 5.2)(SEQ ID NO.14)

[0145] KXKKBKKXK YQFLI KXKBKXK(ERA 5.1)(SEQ ID NO.15)

[0146] KBKKBKK FQILY KBKXK(SEQ ID NO.16)

[0147] KBKKBKK FQILY KBKBK(ERA 5.3)(SEQ ID NO.17)

[0148] KBKK YQFLI KBKXK(ERA 5.4)(SEQ ID NO.18)

[0149] KBKKBK FQILY BKBK (ERA5.5) (SEQ ID NO. 19).

[0150] In one embodiment, the peptide consists of the following sequence: KXKKBKK FQILY KBKXK (SEQ ID NO. 14).

[0151] In one embodiment, the peptide consists of the following sequence: KXKKBKKXK YQFLI KXKBKXK (SEQ ID NO. 15).

[0152] Conjugate

[0153] The peptides of the invention can be covalently linked to a therapeutic molecule to provide a conjugate.

[0154] The therapeutic molecule can be any molecule used to treat a disease. The therapeutic molecule can be selected from: nucleic acids, peptide nucleic acids, antisense oligonucleotides (e.g., PNA, PMO), mRNA, gRNA (e.g., when using CRISPR / Cas9 technology), short interfering RNA, microRNA, antagomiRNA, peptides, cyclic peptides, proteins, pharmaceuticals, drugs, or nanoparticles.

[0155] In one embodiment, the therapeutic molecule is an antisense oligonucleotide.

[0156] Suitably, the antisense oligonucleotide comprises a phosphorodiamidate morpholino oligonucleotide (PMO).

[0157] Alternatively, the oligonucleotide may be a modified PMO or any other charge-neutral oligonucleotide, such as a peptide nucleic acid (PNA), a chemically modified PNA such as γ-PNA (Bahal, Nat. Comm. 2016), an oligonucleotide phosphoramidate (in which the non-bridging oxygen of the phosphate group is replaced by an amine or alkylamine) such as those described in WO2016028187A1, or any other partially or fully charge-neutralized oligonucleotide.

[0158] The therapeutic antisense oligonucleotide sequence can be selected from any available sequence, for example, antisense oligonucleotides for exon skipping in DMD are described in https: / / research-repository.uwa.edu.au / en / publications / antisense-oligonucleotide-indu ced-exon-skipping-across-the-human-, or therapeutic antisense oligonucleotides complementary to ISSN1 or IN7 sequences for the treatment of SMA are described in Zhou, HGT, 2013; and Hammond et al., 2016; and Osman et al., HMG, 2014.

[0159] Optionally, lysine residues can be added to one or both ends of the therapeutic molecule (eg, PMO or PNA) prior to attachment to the peptide to improve water solubility.

[0160] Suitably, the molecular weight of the therapeutic molecule is less than 15,000 Da, less than 10,000 Da, less than 9,000 Da, less than 8,000 Da, less than 7,000 Da, less than 6,000 Da, less than 5,000 Da, less than 5,000 Da, less than 4,000 Da, less than 3,000 Da, less than 2,000 Da or suitably less than 1,000 Da.

[0161] Suitably, the peptide is covalently linked to the therapeutic molecule at the C-terminus.

[0162] Suitably, if desired, the peptide is covalently linked to the therapeutic molecule via a linker. The linker may act as a spacer to separate the peptide sequence from the therapeutic molecule.

[0163] The linker may be selected from any suitable sequence.

[0164] Suitably, the linker is present between the peptide and the therapeutic molecule. Suitably, the linker is a spacer group between the peptide and the therapeutic molecule. Thus, the linker may comprise an artificial amino acid.

[0165] In one embodiment, the conjugate comprises a peptide covalently linked to a therapeutic molecule via a linker. In one embodiment, the conjugate comprises the following structure:

[0166] [Peptide]–[Linker]–[Therapeutic Molecule]

[0167] In one embodiment, the conjugate consists of the structure:

[0168] [Peptide]–[Linker]–[Therapeutic Molecule]

[0169] Suitably, any of the peptides listed herein may be used in the conjugates according to the invention.

[0170] Suitable linkers include, for example, a C-terminal cysteine ​​residue that can form a disulfide, thioether, or thiol-maleimide linkage; a C-terminal aldehyde to form an oxime to click react with a basic amino acid on a peptide or a carboxylic acid moiety on a peptide to form a morpholino linkage, which is covalently conjugated to an amino group to form a carboxamide linkage.

[0171] Suitably, the linker is 1-5 amino acids in length. Suitably, the linker may comprise any linker known in the art.

[0172] Suitably, the linker is selected from any one of the following sequences: G, BC, XC, C, GGC, BBC, BXC, XBC, X, XX, B, BB, BX and XB.

[0173] In one embodiment, the linker is cysteine.

[0174] Suitably, in embodiments where the peptide further comprises a linker, any of the above peptide sequences also suitably comprises a linker at the C-terminus. Suitably, any of the above peptide sequences may comprise a cysteine ​​linker at the C-terminus. Suitably, in such embodiments, the peptide may be selected from any of the following sequences:

[0175] KXKKBKK FQILY KBKXK-C(SEQ ID NO.20)

[0176] KXKKBKKXK YQFLI KXKBKXK-C(SEQ ID NO.21)

[0177] KBKKBKK FQILY KBKXK-C(SEQ ID NO.22)

[0178] KBKKBKK FQILY KBKBK-C(SEQ ID NO.23)

[0179] KBKK YQFLI KBKXK-C(SEQ ID NO.24)

[0180] KBKKBK FQILY BKBK-C (SEQ ID NO. 25).

[0181] In one embodiment, the peptide is conjugated to the therapeutic molecule via a disulfide, thioether, or thiol-maleimide linkage.

[0182] The linker of the conjugate may form part of the therapeutic molecule to which the peptide is attached. Alternatively, attachment of the therapeutic molecule may be directly to the C-terminus of the peptide. Suitably, in such embodiments, no linker is required.

[0183] Alternatively, the peptide can be chemically conjugated to the therapeutic molecule. Chemical linkage can be through, for example, disulfide, alkenyl, alkynyl, aryl, ether, thioether, triazole, amide, carboxamide, urea, thiourea, semicarbazide, carbohydrazide, hydrazine, oxime, phosphate, phosphoramidate, phosphorothioate, boranophosphate, phosphorimidate or thiol-maleimide linkage.

[0184] Optionally, a cysteine ​​can be added to the N-terminus of the therapeutic molecule to allow for disulfide bond formation with the peptide, or the N-terminus can be bromoacetylated to allow for thioether conjugation to the peptide.

[0185] The peptides of the invention may equivalently be covalently linked to imaging molecules to provide conjugates.

[0186] Suitably, the imaging molecule may be any molecule capable of visualising the conjugate. Suitably, the imaging molecule may indicate the location of the conjugate. Suitably, the location of the conjugate in vitro or in vivo. Suitably, there is provided a method of monitoring the location of a conjugate comprising an imaging molecule, the method comprising administering the conjugate to a subject and imaging the subject to locate the conjugate.

[0187] Examples of the imaging molecule include detection molecules, contrast molecules or enhancement molecules. Suitable imaging molecules can be selected from radionuclides; fluorophores; nanoparticles (e.g., nanoshells); nanocages; chromogens (e.g., enzymes), radioisotopes, dyes, radiopaque materials, fluorescent compounds, and combinations thereof.

[0188] Suitably, the imaging molecule is visualized using an imaging technique, which may be a cell imaging technique or a medical imaging technique. Suitable cell imaging techniques include, for example, imaging flow cytometry, fluorescence microscopy, phase contrast microscopy, SEM, TEM. Suitable medical imaging techniques include, for example, X-ray, fluoroscopy, MRI, scintigraphy, SPECT, PET, CT, CAT, FNRI.

[0189] In some cases, the imaging molecule may be considered a diagnostic molecule. Suitably, the diagnostic molecule is capable of diagnosing a disease using the conjugate. Suitably, the diagnosis of a disease may be achieved by determining the location of the conjugate using the imaging molecule. Suitably, there is provided a method of diagnosing a disease, the method comprising administering to a subject an effective amount of a conjugate comprising an imaging molecule and monitoring the location of the conjugate.

[0190] Suitably, further details such as linkage of the conjugate comprising the imaging molecule are the same as those described above with respect to the conjugate comprising the therapeutic molecule.

[0191] Suitably, the peptides of the invention may be covalently linked to therapeutic molecules and imaging molecules to provide conjugates.

[0192] Suitably, the conjugate is capable of penetrating into cells and tissues, suitably into the nucleus of a cell. Suitably, into muscle tissue.

[0193] Pharmaceutical composition

[0194] The conjugates of the present invention can be formulated into pharmaceutical compositions.

[0195] Suitably, the pharmaceutical composition comprises a conjugate of the invention.

[0196] Suitably, the pharmaceutical composition may further comprise a pharmaceutically acceptable diluent, adjuvant or carrier.

[0197] Suitable pharmaceutically acceptable diluents, adjuvants and carriers are well known in the art.

[0198] As used herein, the phrase "pharmaceutically acceptable" refers to those ligands, materials, formulations, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications, commensurate with a reasonable benefit / risk ratio.

[0199] As used herein, the phrase "pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable material, formulation or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, which is involved in carrying or transporting the conjugate from one organ or part of the body to another organ or part of the body. Each cell penetrating peptide must be "acceptable" in the sense of being compatible with the other components of the composition, such as peptides and therapeutic molecules, and not harmful to the individual. Lyophilized compositions that can be reconstituted and administered are also within the scope of the compositions of the present invention.

[0200] Pharmaceutically acceptable carriers may be, for example, excipients, vehicles, diluents, and combinations thereof. For example, when the compositions are administered orally, they may be formulated into tablets, capsules, granules, powders, or syrups; or for parenteral administration, they may be formulated into injections, drip preparations, or suppositories. These compositions may be prepared by conventional methods, and if desired, the active compound (i.e., conjugate) may be mixed with any conventional additives, such as excipients, binders, disintegrants, lubricants, flavoring agents, solubilizers, suspending agents, emulsifiers, coating agents, or combinations thereof.

[0201] It should be understood that the pharmaceutical compositions of the present disclosure may further include other known therapeutic agents, drugs, modifications of the compounds into prodrugs, etc., for medical use to alleviate, regulate, prevent and treat the diseases, disorders and conditions described herein.

[0202] Suitably, the pharmaceutical composition is for use as a medicament. Suitably, it is for use as a medicament in the same manner as the conjugates described herein. All features described herein in relation to medical treatment using the conjugates apply to the pharmaceutical composition.

[0203] Thus, in another aspect of the invention, there is provided a pharmaceutical composition according to the fourth aspect for use as a medicament. In another aspect, there is provided a method of treating a disease condition in a subject comprising administering to the subject an effective amount of a pharmaceutical composition according to the fourth aspect.

[0204] Medical Uses

[0205] The conjugate comprising the peptide of the present invention can be used as a drug for treating diseases.

[0206] The medicament may be in the form of a pharmaceutical composition as defined above.

[0207] Also provided is a method of treating a patient or subject in need of treatment for a disease condition, the method comprising the step of administering to the patient or subject a therapeutically effective amount of the conjugate.

[0208] Suitably, medical treatment requires delivery of the therapeutic molecule into a cell, suitably into the nucleus of a cell.

[0209] The disease to be treated may include any disease in which improved penetration of cellular and / or nuclear membranes by a therapeutic molecule can result in an improved therapeutic effect.

[0210] Suitably, the conjugate is for use in treating a disease of the neuromuscular system.

[0211] The conjugates comprising the peptides of the invention are suitable for the treatment of genetic diseases of the neuromuscular system. The conjugates comprising the peptides of the invention are suitable for the treatment of genetic neuromuscular diseases. In a suitable embodiment, a conjugate according to the second aspect is provided for the treatment of genetic diseases of the neuromuscular system. Suitably, the conjugate is for the treatment of hereditary genetic diseases. Suitably, the conjugate is for the treatment of hereditary genetic diseases of the neuromuscular system. Suitably, the conjugate is for the treatment of hereditary genetic neuromuscular diseases. Suitably, the conjugate is for the treatment of hereditary X-linked genetic diseases of the neuromuscular system. Suitably, the conjugate is for the treatment of hereditary X-linked neuromuscular diseases.

[0212] Suitably, the conjugate is used to treat a disease selected from the group consisting of Duchenne muscular dystrophy (DMD), Bucher muscular dystrophy (BMD), Menkes disease, β-thalassemia, dementia, Parkinson's disease, spinal muscular atrophy (SMA), myotonic dystrophy (DM1 or DM2), Huntington's disease, Hutchinson-Gilford progeria syndrome, ataxia telangiectasia or cancer.

[0213] Suitably, the conjugate is used to treat a disease caused by a splicing defect. In such an embodiment, the therapeutic molecule may comprise an oligonucleotide capable of preventing or correcting a splicing defect and / or increasing the production of correctly spliced ​​mRNA molecules.

[0214] Suitably, the conjugate according to the invention is capable of inducing a splicing correction in an mRNA molecule of at most 10%, at most 20%, at most 30%, at most 40%, at most 50%, at most 60%, at most 70%, at most 80%, at most 90% or at most 100%.

[0215] Suitably, the conjugates according to the invention are capable of inducing splicing correction in mRNA molecules of 30% to 90% at a dose that causes less toxicity compared to a control peptide (as described in the Examples section).

[0216] Suitably, the patient or subject to be treated may be any animal or human. Suitably, the patient or subject may be a non-human mammal. Suitably, the patient or subject may be male or female. In one embodiment, the subject is male.

[0217] Suitably, the patient or subject to be treated may be of any age. Suitably, the patient or subject to be treated is aged 0-40 years, suitably 0-30 years, suitably 0-25 years, suitably 0-20 years.

[0218] Suitably, the conjugate is for systemic administration to a subject, for example, by intramedullary, intrathecal, intraventricular, intravitreal, enteral, parenteral, intravenous, intraarterial, intramuscular, intratumoral, subcutaneous, oral or nasal routes.

[0219] In one embodiment, the conjugate is for intravenous administration to a subject.

[0220] In one embodiment, the conjugate is for intravenous administration to a subject by injection.

[0221] Suitably, the conjugate is administered to a subject in a "therapeutically effective amount", by which is meant an amount sufficient to show benefit to the individual. The actual amount administered, as well as the rate and time course of administration, will depend on the nature and severity of the disease being treated. Decisions on dosage are the responsibility of general practitioners and other physicians. Examples of such techniques and regimens can be found in Remington's Pharmaceutical Sciences, 20th edition, 2000, pub. Lippincott, Williams & Wilkins.

[0222] Exemplary dosages can be 0.01 mg / kg to 50 mg / kg, 0.05 mg / kg to 40 mg / kg, 0.1 mg / kg to 30 mg / kg, 0.5 mg / kg to 18 mg / kg, 1 mg / kg to 16 mg / kg, 2 mg / kg to 15 mg / kg, 5 mg / kg to 10 mg / kg, 10 mg / kg to 20 mg / kg, 12 mg / kg to 18 mg / kg, 13 mg / kg to 17 mg / kg.

[0223] Advantageously, the dosage of the conjugates of the invention is an order of magnitude lower than the dosage required to be effective by administering the therapeutic molecule alone.

[0224] Suitably, following administration of the conjugate of the invention, one or more markers of toxicity are significantly reduced compared to prior conjugates using currently available peptide vectors.

[0225] A suitable toxicity marker may be a nephrotoxicity marker.

[0226] Appropriate toxicity markers include KIM-1, NGAL, BUN, creatinine, alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase.

[0227] Suitably, the level of at least one of KIM-1, NGAL and BUN is reduced following administration of the conjugate of the invention when compared to prior conjugates using currently available peptide vectors.

[0228] Suitably, the levels of each of KIM-1, NGAL and BUN are reduced following administration of the conjugate of the invention when compared to prior conjugates using currently available peptide vectors.

[0229] Suitably, the level of the or each marker is significantly reduced when compared to prior conjugates using currently available peptide vectors.

[0230] Suitably, the level of the or each marker is reduced by up to 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% following administration of the conjugate of the invention when compared to prior conjugates using currently available peptide vectors.

[0231] Advantageously, the toxicity of the peptides, and thus the resulting conjugates, is significantly reduced compared to existing cell penetrating peptides and conjugates. In particular, KIM-1 and NGAL-1 are markers of toxicity that are significantly reduced by up to 120-fold compared to existing conjugates using currently available peptide vectors.

[0232] Nucleic Acids and Hosts

[0233] The peptides of the present invention can be prepared by any standard protein synthesis method (eg chemical synthesis, semi-chemical synthesis) or by using an expression system.

[0234] Therefore, the present invention also relates to a nucleotide sequence comprising or consisting of DNA encoding the peptide, an expression system (e.g., a vector comprising the sequence and sequences required for expression and control of expression), and host cells and host organisms transformed by the expression system.

[0235] Therefore, there is also provided a nucleic acid encoding a peptide according to the invention.

[0236] Suitably, the nucleic acid may be provided in isolated or purified form.

[0237] Also provided are expression vectors comprising nucleic acids encoding the peptides according to the invention.

[0238] Suitably, the vector is a plasmid.

[0239] Suitably, the vector comprises a regulatory sequence (e.g., a promoter) operably linked to a nucleic acid encoding a peptide according to the invention. Suitably, the expression vector is capable of expressing the peptide when transfected into a suitable cell (e.g., a mammalian, bacterial or fungal cell).

[0240] Also provided is a host cell comprising the expression vector of the invention.

[0241] The expression vector can be selected according to the host cell into which the nucleic acid of the present invention can be inserted. Such transformation of the host cell involves conventional techniques, such as those taught in Sambrook et al. [Sambrook, J., Russell, D. (2001) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, NY, USA]. It is within the capabilities of those skilled in the art to select an appropriate vector. Suitable vectors include plasmids, bacteriophages, cosmids and viruses.

[0242] The produced peptides may be isolated and purified from the host cells by any suitable method, such as precipitation or chromatography, such as affinity chromatography.

[0243] Appropriate vectors, hosts and recombinant techniques are well known in the art.

[0244] In this specification, the term "operably linked" may include a situation where the selected nucleotide sequence and the regulatory nucleotide sequence are covalently linked in such a way that the expression of the nucleotide coding sequence is under the control of the regulatory sequence, so that the regulatory sequence can affect the transcription of the nucleotide coding sequence that forms part or all of the selected nucleotide sequence. The resulting transcript can then be translated into the desired peptide under appropriate circumstances. BRIEF DESCRIPTION OF THE DRAWINGS

[0245] Certain embodiments of the present invention will now be described with reference to the following figures and tables, in which:

[0246] Figure 1 : Shows the comparative delivery of conjugates to target tissues in DM1 adult mice (HSA-LR mice aged 8-12 weeks). Evaluation of the biodistribution of ERA5.1-CAG7 and ERA5.2-CAG7 showed that after two weeks of 30 mg / kg (A) and 7.5 mg / kg (B), compared with naked PMO and benchmark conjugates (R6Gly-CAG7, which contains peptides used by Sarepta in clinical trials of DMD patients) and naked PMO (3X200 mg / kg) (all conjugates contain the same PMOCAG7 sequence), the best delivery was obtained in severely affected tissues in DM1. The data show that after two weeks of injection of 30 mg / kg, the concentration of PMO in muscle tissue is still>1nM, while low pM is detected after naked PMO injection (although the molar concentration difference between naked PMO and conjugate treatment is>20 times). Data are expressed as mean + / - SEM.

[0247] Figure 2: The CPP-PMO conjugates of the invention are shown to correct the splicing defects that lead to DM1 pathology. Systemic delivery of the conjugate (IV, tail vein) at 30 mg / kg corrects the mis-splicing of Mbnl-dependent transcripts in the gastrocnemius muscle of adult mice with DM1 (8-12 week old HSA-LR mice). RT-PCR analysis of splicing of Mbnl1 exon 5 (A) and Clcn1 exon 7a (B), the most widely used DM1 biomarkers, is shown (data are median ± SEM).

[0248] Figure 3 : Shows HSA transcript levels (containing toxic RNA repeats) normalized to P0 in 8-12 week old HSA-LR mice treated with the conjugates of the invention (IV administration, 30 mg / kg) for 2 weeks, compared to the benchmark conjugate R6Gly-CAG7 (data are median ± SEM).

[0249] Figure 4 : Shows the effect on myotonia grade in HSA-LR mice (8-12 weeks old) after administration (IV, tail vein) of a conjugate of the peptide of the invention with the PMO CAG7 therapeutic agent, compared to a benchmark conjugate (R6Gly-CAG7). ERA5.1-CAG7 and ERA5.2-CAG7 corrected wild-type levels of myotonia after 1 week of treatment at 30 mg / kg (error bars, SEM).

[0250] Figure 5 : Shows Kim-1 urine marker levels (biomarker for nephrotoxicity) for conjugates of existing PIP peptides compared to conjugates of the peptides of the present invention with PMO therapeutic agents 2 or 7 days after administration of 7.5 mg / kg or 30 mg / kg. Toxicological analysis showed no significant changes at doses that normalize the DM1 phenotype (according to Figure 3 and 4 ). Kim-1 was measured by ELISA (R&D cat#MKM100) where samples were diluted to fit the standard curve. Values ​​were normalized to urine creatinine levels to calculate urine protein concentrations. Kim-1 levels were similar to saline control injections, compared to the fold increase induced by the existing Pip series peptide vectors.

[0251] Figure 6:Show that DM1 myoblasts (immortalized myoblasts from DM1 patients) containing 2600 repeats in the 3'UTR of DMPK mRNA were treated with the conjugate of the present invention 48 hours later, using a (CAG)5Cy3 labeled probe for detecting mutant DMPK RNA, the number of toxic DMPK foci was reduced by fluorescence in situ hybridization. The results 48 hours after transfection with different doses of the conjugate (shown as 10uM) showed that the cell viability of myoblasts or hepatocytes was not reduced.

[0252] Figure 7 : Shows cell viability of DM1 patient myoblasts (A) or wild-type hepatocytes (B) with 2600 CTG repeats transfected with different ERA5-[CAG]7 conjugates and comparative conjugates 48 hours later. Compared with conjugates formed with existing peptide vectors Pip6a and Pip9b2, the concentration of ERA5-CAG7 PMO conjugates can be increased several-fold from therapeutic levels (according to Figure 6 ), without causing hepatocyte cell death. (Error bars, SEM).

[0253] Throughout the description and claims of this specification, the words "comprise" and "include" and their variations mean "including but not limited to", and they are not intended to (and do not) exclude other parts, additives, components, integers or steps. Throughout the description and claims of this specification, the singular includes the plural, unless the context requires otherwise. In particular, where the indefinite article is used, the specification should be understood as including both the plural and the singular, unless the context requires otherwise.

[0254] Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. All features disclosed in this specification (including any accompanying claims, abstract and drawings) and / or all steps of any method or process so disclosed may be combined in any combination, except where at least some of these features and / or steps are mutually exclusive combinations.

[0255] The invention is not limited to the details of any foregoing embodiments. The invention extends to any novel one or any novel combination of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one or any novel combination of the steps of any method or process so disclosed. The reader is advised that all papers and documents related to this application filed concurrently with or before this specification are disclosed, which are open to public inspection together with this specification, and the contents of all these papers and documents are incorporated herein by reference. Example

[0256] method

[0257] Peptide synthesis

[0258] Using CEM Liberty Blue TM Microwave peptide synthesizer (Buckingham, UK) and Fmoc chemistry were used to extend the peptide chain on a 0.1 mmol scale, as recommended by the manufacturer. Coupling conditions utilized PyBOP and DIEA (5 equivalents and 10 equivalents, respectively), while Fmoc removal used 20% piperidine in DMF. Once the synthesis was complete, the resin was washed with DMF (3x 5 mL), and the N-terminal of the solid phase bound peptide was acetylated with acetic anhydride at room temperature in the presence of DIEA. After N-terminal acetylation, the peptide resin was washed with DMF (3x 5 mL) and DCM (3x 5 mL). After drying the peptidyl resin, the peptide was cleaved from the solid support by treatment with a cleavage mixture consisting of trifluoroacetic acid (TFA): H2O: triisopropylsilane (TIS): 2,3'-(ethylenedioxy)bisethanethiol (94%: 2.5%: 2.5%: 1%, 10 mL / g). The reaction lasted for 1 hour at room temperature, followed by the usual ether precipitation, HPLC analysis and MALDI-TOF characterization. The peptide was purified on a RP-C18 column (21.2 x 250 mm, Phenomenex) using a 1260 Infinity II preparative HPLC Agilent system using a linear gradient of 0.1% TFA CH3CN in 0.1% TFA / H2O (from 5 to 50 in 30 minutes) at a flow rate of 15 mL / min.

[0259] Synthesis of PMO-peptide conjugates vs maleimide conjugates

[0260] The 21-mer PMO antisense sequence of the triplet repeat (CAGCAGCAGCAGCAGCAGCAGCAG (SEQ ID NO: 26), also known as CAG7, was purchased from Gene Tools (USA). Peptide conjugation was performed by dissolving PMO (2000 nmole) in 50 mM sodium phosphate buffer (pH 7.2) containing 20% ​​acetonitrile at a concentration of 4 mM. A 2-fold molar excess of the cross-linker 3-maleimidopropionic acid N-hydroxysuccinimide ester (GMBS, ThermoScientific) was added and the reaction mixture was kept at room temperature for 1 hour. The maleimide-functionalized PMO was then purified using a PD miditrap G-25 column, lyophilized, and then dissolved in 50 mM sodium phosphate buffer (pH 6.5) containing 20% ​​acetonitrile at a concentration of 4 mM. Two equivalents of peptide were added to the maleimide-PMO and the reaction was incubated for 1 hour at room temperature as monitored by HPLC. The reaction was quantified using a modified Gilson The HPLC system purifies the solution by ion exchange chromatography. The PMO-peptide conjugate is purified on an ion exchange column (pre-loaded with Resource S, GE Healthcare) using a linear gradient of sodium phosphate buffer (25mM, pH 7.0) containing 20% ​​CH3CN. The conjugate is eluted from the column using a sodium chloride solution (1M) at a flow rate of 6mL / min. The fractions are collected manually, and the desired compound is immediately combined and desalted. Excess salt can be removed from the peptide-PMO conjugate by filtering the fractions collected after ion exchange using an Amiconultra-15 3K centrifugal filter device. The conjugate is lyophilized and analyzed by MALDI-TOF and RP-HPLC. Before use, the conjugate is dissolved in sterile water and filtered through a 0.22m cellulose acetate membrane. The concentration of peptide-PMO is determined by the molar absorption of the conjugate at 265nm in a 0.1N HCl solution. The average yield is about 20% based on the PMO starting material.

[0261] Table 1:

[0262]

[0263]

[0264] Table 1: Synthesized peptides used for testing in the examples. Conjugates formed with R6Gly, Pip6a and Pip9b2 are comparable. Ac indicates an N-terminal acetyl group, C indicates a cysteine ​​linker. Gly indicates a glycine linker.

[0265] Synthesis of peptide-PMO conjugate library

[0266] The 21-mer PMO antisense sequence for triplet repeats, CAGCAGCAGCAGCAGCAGCAG (SEQ ID NO. 26), also known as [CAG]7, was used. The PMO sequence targeting the CUG / CTG expanded repeat sequence (5′-CAGCAGCAGCAGCAGCAGCAG-3′ (SEQ ID NO. 26)) was purchased from Gene Tools LLC. This is the [CAG]7 PMO mentioned elsewhere in this article. The peptide was conjugated to the 3′ end of the PMO via its C-terminal carboxyl group. This was achieved using 2.5 and 2 equivalents of PyBOP and HOAt, respectively, in NMP, with 2.5 equivalents of DIPEA and a 2.5-fold excess of peptide relative to the PMO dissolved in DMSO. Typically, to a solution of the peptide (2500 nmol) in N-methylpyrrolidone (NMP, 80 μL) was added PyBOP (19.2 μL of a 0.3 M solution in NMP), HOAt (16.7 μL of a 0.3 M solution in NMP), DIPEA (1.0 mL) and PMO (180 μL of a 10 mM solution in DMSO). The mixture was placed at 40°C for 2.5 hours. The solution was purified by ion exchange chromatography using a modified Gilson HPLC system. The PMO-peptide conjugate was purified on an ion exchange column (Resource S 4 mL, GE Healthcare) using a linear gradient of sodium phosphate buffer (25 mM, pH 7.0) containing 20% ​​CH3CN. The conjugate was eluted from the column using sodium chloride solution (1 M) at a flow rate of 4 mL min -1 or 6 mL / min -1 The fractions containing the desired compound were immediately combined and desalted. The fractions collected after ion exchange were filtered through an ultra-15 3K centrifugal filter unit to remove excess salt from the peptide-PMO conjugate. The conjugate was lyophilized and analyzed by MALDI-TOF. Before use, the conjugate was dissolved in sterile water and filtered through a 0.22 μm cellulose acetate membrane. The concentration of peptide-PMO was determined by the molar absorption of the conjugate at 265 nm in 0.1 N HCl solution.

[0267] Animal models and ASO injection

[0268] Experiments were conducted at the University of Oxford in accordance with UK law. Intravenous injections of HSA-LR mice were performed by a single injection via the tail vein. Doses of 7.5, 30, or 40 mg / kg of peptide-PMO-CAG7 or 200 mg / kg of PMO were diluted in 0.9% saline and administered at 5-6 μL / g body weight. Myotonia was assessed and tissues were harvested 2 weeks after the last injection.

[0269] Cell culture and peptide-PMO treatment

[0270] Immortalized myoblasts of healthy individuals or DM1 patients with 2600 CTG repeats were cultured in a growth medium consisting of a M199:DMEM mixture (1:4 ratio, Life technologies), supplemented with 20% FBS (Life technologies), 50 μg / ml gentamicin (Life Technologies), 25 μg / ml fetuin, 0.5 ng / ml bFGF, 5 ng / ml EGF and 0.2 μg / ml dexamethasone (Sigma-Aldrich). For myoblasts, myogenic differentiation was induced by switching the confluent cell culture to a DMEM medium supplemented with 5 μg / ml insulin (Sigma-Aldrich). For treatment, WT or DM1 cells were differentiated for 4 days. Then, the culture medium was replaced with a fresh differentiation medium containing a peptide-PMO conjugate at a concentration of 1, 2, 5, 10, 20 or 40 μM. Cells were harvested 48 hours after treatment for analysis.

[0271] RNA isolation, RT-PCR and qPCR analysis

[0272] For mouse tissue: Before RNA extraction, muscle was destroyed in TriReagent (Sigma-Aldrich) using Fastprep system and Lysing Matrix D tube (MPbiomedicals). For human cells: Before RNA extraction, cells were lysed at 55°C for 45 minutes in proteinase K buffer (500mM NaCl, 10mM Tris-HCl, pH7.2, 1.5mM MgCl2, 10mM EDTA, 2% SDS and 0.5mg / ml proteinase K). Total RNA was isolated using TriReagent according to the manufacturer's protocol. According to the manufacturer's instructions, one microgram of RNA was reverse transcribed using M-MLV first-chain synthesis system (Life Technologies), a total of 20 μL. Subsequently, one microliter of cDNA preparation was used for semi-quantitative PCR analysis according to standard protocols (ReddyMix, Thermo Scientific). Primers are shown in Table 2 below:

[0273] Table 2

[0274]

[0275]

[0276] PCR amplification was performed for 25-35 cycles within the linear amplification range for each gene. PCR products were separated on 1.5-2% agarose gels, stained with ethidium bromide, and quantified using ImageJ software. The ratio of exon inclusion was quantified as the percentage of inclusion relative to the total intensity of the isoform signal. To quantify mRNA expression, real-time PCR was performed according to the manufacturer's instructions. PCR cycles were a 15-minute denaturation step followed by 50 cycles of denaturation at 94°C for 15 seconds, annealing at 58°C for 20 seconds, and extension at 72°C for 20 seconds.

[0277] Fluorescence in situ hybridization / immunofluorescence

[0278] Fluorescence in situ hybridization (FISH) experiments were performed as described previously using a Cy3-labeled 2'OMe(CAG)7 probe (Eurogentec). For combined FISH-immunofluorescence experiments, immunofluorescence staining was performed after the last wash of FISH with a rabbit polyclonal anti-MBNL1 antibody followed by a secondary Alexa Fluor 488-conjugated goat anti-rabbit (1:500, LifeTechnologies) antibody.

[0279] ELISA-based measurement of oligonucleotide concentrations in tissues

[0280] A custom hybridization-based ELISA was developed to determine the concentration of PMO oligonucleotides using a phosphorothioate probe with a phosphorothioate linkage (sequence (5'->3')[DIG]C*T*G*C*T*G*C*TGCTGCT*G*C*T*G*C*T*G[BIO] (SEQ ID NO:39); * represents a phosphorothioate bond) dual-labeled with digoxigenin and biotin. The assay had a linear detection range of 5-250 pM (R2>0.99) in mouse serum and tissue lysates. The probe was used to detect peptide-PMO or naked PMO concentrations in eight different tissues (brain, kidney, liver, lung, heart, diaphragm, gastrocnemius, and quadriceps) from treated HSA-LR mice.

[0281] result

[0282] In this work, the inventors used lysine-rich cell-penetrating peptides with specific structures and showed that this peptide conjugated with [CAG]7 morpholino phosphorodiamidate oligomers (PMOs) significantly enhanced ASO delivery into skeletal and cardiac muscle of DM1 model HSA-LR mice after systemic administration compared to unconjugated PMOs and other peptide carrier conjugate strategies. Thus, low-dose treatment of the conjugates formed by peptide-[CAG]7PMOs targeting pathological amplification claimed herein was sufficient to reverse both splicing defects and myotonia in DM1 mice (HSA-LR). In addition, treated DM1 patient-derived muscle cells (myoblasts) showed that the peptide-[CAG]7PMO conjugates claimed herein specifically targeted mutant CUGexp-DMPK transcripts, thereby eliminating the harmful sequestration of MBNL1 splicing factors by nuclear RNA foci and the resulting loss of MBNL1 function, which caused splicing defects and muscle dysfunction. Our results demonstrate that the peptide-[CAG]7PMO conjugates as claimed herein induce highly efficient correction of DM1-associated phenotypes at both the molecular and functional levels and strongly support the use of these peptide conjugates for systemic corrective therapy of DM1.

[0283] The inventors have obtained data for conjugates containing peptide carriers without R residues, which have a wider therapeutic window and a safer toxicology profile than previous cell-penetrating peptides and therefore constitute more promising candidates for testing in DM1 patients. These new generation of so-called ERA5 peptides have shown efficient delivery of antisense cargo (CAG7-PMO) to hard-to-reach tissues such as cardiac and skeletal muscle ( Figure 1 ). The biodistribution of naked PMO and conjugates formed with carrier peptides ERA5.1, ERA5.2 and benchmark R6Gly was evaluated by ELISA to quantify the delivery of peptide-[CAG]7PMO conjugates. Detection of PMO in tissues severely affected in DM1, such as skeletal muscle and heart, is important for drug delivery development. A single intravenous injection of 30 mg / kg of peptide-[CAG]7PMO conjugate or 3 injections of 200 mg / kg of naked PMO were administered to HSA-LR mice (a total of 600 mg / kg). PMO detection in gastrocnemius, quadriceps, diaphragm, heart and brain was analyzed 2 weeks after administration. Unconjugated naked [CAG]7PMO had low to undetectable levels in all tissues tested, but the levels of [CAG]7PMO conjugated to peptide carriers ERA5.1 and ERA5.2 were detected to be higher than the benchmark peptide R6Gly. Overall, 1 nM to 7 nM of peptide-[CAG]7PMO conjugates were detected in the heart, quadriceps, gastrocnemius, and diaphragm after 2 weeks of 30 mg / kg injection ( Figure 1 , A), while after 7.5m / kg treatment, it was 0.3 to 1.2nM ( Figure 2 , B).

[0284] The inventors tested whether these new peptides are also effective in correcting myotonia and splicing changes in HSA-LR mice. To this end, the main peptide carrier of the ERA5 series was compared with the benchmark peptide carrier R6Gly. The inventors were able to show that when administered systemically (IV, tail vein), the conjugate comprising the ERA5 peptide and the antisense cargo (CAG7 PMO) can correct the splicing defects in muscle ( Figure 2 ). Thus, the conjugate of the present invention corrected 50-90% of the mis-splicing of Clcn1 (ex7a) and Mbnl1 (ex5) in HSA-LR gastrocnemius muscle after two weeks of treatment in 8-12 week old HSA-LR mice ( Figure 2 These treatments also reduced the levels of HSA transcripts containing toxic repeats when normalized to P0 2 weeks after PPMO intravenous (IV) administration (30 mg / kg) ( Figure 3 ). These molecular corrections are associated with the reversal of DM1 pathology. For example, Figure 4 It is shown how myotonia was corrected to wild-type levels one week after administration of conjugates formed from ERA5.1 and ERA5.2 (30 mg / kg). Importantly, the reversal of pathology was independent of changes in urinary toxicity biomarkers (nephrotoxicity, Kim-1 levels). Kim-1 levels were similar to saline control injections after administration of conjugates formed from ERA5.1, ERA5.2, ERA5.3, ERA5.4, and ERA5.5, in contrast to the fold increase typically caused by equivalent R-substituted vectors (pip6a and pip9b2), even for lower doses, 7.5 mg / kg 2 days after IV administration ( Figure 5 ). It is noteworthy that conjugates formed with existing peptide vectors such as Pip6a-[CAG]7PMO or Pip9b2-[CAG]7 could not be tested at >20 mg / kg, otherwise it would result in high mortality in mice, in contrast to the conjugates of the present invention, the concentration of which could be increased more than 5-fold without causing any mortality.

[0285] Conjugates with carrier peptides of the ERA5 series reduced the number of foci (2600 CTG repeats) containing mutant DMPK RNA per nucleus in DM1 differentiated myoblasts 2 days after transfection with 10 uM PPMO ( Figure 6 None of the concentrations tested resulted in reduced cell viability in human hepatocytes (1-40 μM), in contrast to similar comparative conjugates formed with known "Pip" carrier peptides; Pip6a-PMO and Pip9b2-PMO induced significant cell death (>50%) at 40 μM ( Figure 7Many of the concentrations tested did not result in reduced cell viability in human myoblasts and performed better than similar comparative conjugates formed from known "Pip" carrier peptides, Pip6a-PMO and Pip9b2-PMO, which induced cell death at lower doses ( Figure 7 ).

[0286] Through these preliminary data, the inventors demonstrated that the conjugate of ERA5 peptide with [CAG]7PMO was more active than the benchmark conjugate R6Gly-CAG7 ( Figure 1 , 2 , 3 and 4), and have a wider therapeutic window than the PIP series due to their activity ( Figure 5 ). Efficacy and toxicology data indicate that the claimed conjugates with the ERA5 series of carrier peptides are particularly active, capable of blocking the sequestration of MBNL1 by expanded CTG repeats in individuals affected by DM1, and causing low toxicity. These conjugates are capable of correcting the DM1 phenotype. These new conjugates also have a wider therapeutic window than existing peptide carrier conjugates, so they are closer to being achieved in the clinic.

[0287] In summary, the inventors have demonstrated strong evidence supporting that: (1) peptide-[CAG]7PMO blocks the pathological interaction of MBNL1 with nuclear mutant CUGexp-RNA and rescues downstream effects on RNA splicing; (2) the peptide-conjugated antisense oligonucleotide approach enables therapeutic delivery to inaccessible tissues such as the heart in the diaphragm; (3) the potent effect of [CAG]7PMO directly targeting the disease mutation combined with the ability of peptide vector technology to efficiently deliver therapeutics in vivo, together, strongly reversed the DM1 phenotype in skeletal muscle DM1 mice (HSA-LR) to wild-type levels. These evidences strongly suggest that peptide-[CAG]7 conjugates may have a strong disease-modifying effect in DM1.

[0288] Indeed, the experiments showed that the effects we observed in HSA-LR mice not only prevented the progression of DM1 pathology, but also led to a reversal of the disease phenotype. Amplified CUG transcripts were already expressed in pups, and HSA-LR mice developed significant myotonia at 1 month of age. The animals used to generate the results supporting this application were treated at least 2 months of age and even 7 months of age, well beyond the time point at which the molecular and functional phenotypes of DM1 develop.

[0289] in conclusion

[0290] Conjugates containing the ERA5 carrier peptide and [CAG]7PMO showed positive biodistribution evaluations, revealing optimal delivery to tissues severely affected in DM1, such as skeletal and cardiac muscles.

[0291] Conjugates (10 μM) containing the ERA5 carrier peptide and [CAG]7PMO were able to reduce the number of nuclear foci by >50% in DM1 patient myoblasts and controls (at doses that did not reduce cell viability). In contrast to comparative conjugates formed with other carrier peptides (PIP series) that induced significant cell death (>50%) at concentrations of 20 μM or higher, none of the concentrations tested resulted in a reduction in cell viability (1-40 μM).

[0292] Conjugates comprising an ERA5 carrier peptide (lysine-rich) and [CAG]7PMO induced 30%-90% splicing correction in Clcn1 exon 7a and Mbnl1 exon 5 at 30 mg / kg (IV), and this dose of ERA5 conjugate was less toxic in HSA-LR mice than comparable conjugates formed with other carrier peptides (PIP series, arginine-rich) at 7.5 mg / kg.

[0293] The ERA5[CAG]7PMO conjugate was more potent than the benchmark conjugate R6gly[CAG]7PMO, correcting splicing and reducing myotonia to wild-type levels 1 week after a single injection of 30 mg / kg (IV).

[0294] Urine biochemical testing for renal function showed no changes compared to saline treatment of HSA-LR or wild-type mice, whereas HSA-LR Kim1 levels were slightly altered after treatment with =>30 mg / kg (IV) of [CAG]7PMO of the ERA5 carrier peptide and comparative conjugates with other carrier peptides (PIP series) at a dose of 7.5 mg / kg.

[0295] sequence

[0296] KXKKBKK (SEQ ID NO: 1)

[0297] KXKKBKKXK (SEQ ID NO: 2)

[0298] KBKKBKK (SEQ ID NO: 3)

[0299] KBKKBK (SEQ ID NO:4)

[0300] KBKK (SEQ ID NO:5)

[0301] KXKBKXK (SEQ ID NO:6)

[0302] KBKXK (SEQ ID NO:7)

[0303] KBKBK (SEQ ID NO:8)

[0304] BKBK(SEQ ID NO:9)

[0305] YQFLI(SEQ ID NO:10)

[0306] ILFQY(SEQ ID NO:11)

[0307] YRLFI(SEQ ID NO:12)

[0308] FQILY(SEQ ID NO:13)

[0309] KXKKBKK FQILY KBKXK(ERA5.2)(SEQ ID NO:14)

[0310] KXKBKXK YQFLI KXKBKXK(ERA5.1)(SEQ ID NO:15)

[0311] KBKKBKK FQILY KBKXK (SEQ ID NO:16)

[0312] KBKKBK FQILY KBKBK(ERA5.3)(SEQ ID NO:17)

[0313] KBKK YQFLI KBKXK(ERA5.4)(SEQ ID NO:18)

[0314] KBKKBK FQILY BKBK(ERA5.5)(SEQ ID NO:19)

[0315] KXKKBKK FQILY KBKXK-C (SEQ ID NO.20)

[0316] KXKBKXK YQFLI KXKBKXK-C (SEQ ID NO.21)

[0317] KBKKBKK FQILY KBKXK-C (SEQ ID NO.22)

[0318] KBKKBK FQILY KBKBK-C (SEQ ID NO.23)

[0319] KBKK YQFLI KBKXK-C(SEQ ID NO.24)

[0320] KBKKBK FQILY BKBK-C (SEQ ID NO.25)

[0321] <h2 style=";text-align:left;direction:ltr">CAGCAGCAGCAGCAGCAG(SEQ ID NO.26)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0322] <h2 style=";text-align:left;direction:ltr"> Ac-KXKKBKKXK YQFLI KXKBKXK-C(ERA5.1)(SEQ ID NO.27)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0323] <h2 style=";text-align:left;direction:ltr"> Ac-KBKKBKK FQILY KBKXK-C(SEQ ID NO.28)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0324] <h2 style=";text-align:left;direction:ltr"> Ac-KXKKBKK FQILY KBKXK-C(ERA5.2)(SEQ ID NO.41)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0325] <h2 style=";text-align:left;direction:ltr"> Ac-KBKKBKK FQILY KBKBK-C(ERA5.3)(SEQ ID NO.29)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0326] <h2 style=";text-align:left;direction:ltr"> Ac-KBKK YQFLI KBKXK-C(ERA5.4)(SEQ ID NO.30)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0327] <h2 style=";text-align:left;direction:ltr"> Ac-KBKKBK FQILY BKBK-C(ERA5.5)(SEQ ID NO.31)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0328] <h2 style=";text-align:left;direction:ltr"> Ac-RRRRRR-Gly(SEQ ID NO.32)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0329] <h2 style=";text-align:left;direction:ltr"> Ac-RXRRBRRXR-YQFLI-RXRBRXR-C(SEQ ID NO.33)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0330] <h2 style=";text-align:left;direction:ltr"> Ac-RXRRBRR-FQILY-RBRXR-C(SEQ ID NO.34)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0331] <h2 style=";text-align:left;direction:ltr"> GCTGCCCAATACCAGGTCAAC(SEQ ID NO.35)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0332] <h2 style=";text-align:left;direction:ltr"> TGGTGGGAGAAATGCTGTATGC(SEQ ID NO.36)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0333] <h2 style=";text-align:left;direction:ltr"> TTCACATCGCCAGCATCTGTGC(SEQ ID NO.37)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0334] <h2 style=";text-align:left;direction:ltr"> CACGGAACACAAAGGCACTGAATGT(SEQ ID NO.38)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0335] <h2 style=";text-align:left;direction:ltr"> [DIG]C*T*G*C*T*G*C*TGCTGCT*G*C*T*G*C*T*G[BIO](SEQ ID NO.39)<h2 style=";text-align:left;direction:ltr">

[0336] RRRRRR(SEQ ID NO.40)

Claims

1. A peptide having a total length of 40 amino acid residues or less, said peptide comprising at least two cationic domains and at least one hydrophobic domain, wherein said at least two cationic domains each comprise a plurality of lysine residues, and wherein said peptide does not contain arginine.

2. The peptide according to claim 1, wherein the at least two cationic domains each comprise cationic amino acid residues, preferably the at least two cationic domains each comprise at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% of cationic amino acid residues, more preferably wherein the cationic amino acid residues are selected from lysine or histidine.

3. The peptide according to claim 1 or 2, wherein the at least two cationic domains comprise one or more amino acid residues selected from the group consisting of lysine, aminocaproic acid and β-alanine, preferably wherein the at least two cationic domains consist of amino acid residues selected from the group consisting of lysine, aminocaproic acid and β-alanine.

4. The peptide according to any one of claims 1 to 3, wherein each of the at least two cationic domains comprises a majority of lysine residues, preferably wherein each of the at least two cationic domains comprises at least 60%, at least 70%, at least 80%, at least 90% lysine residues.

5. The peptide according to any one of claims 1 to 4, wherein the at least two cationic domains each comprise 2 to 10 lysine residues, preferably 2 to 6 lysine residues.

6. The peptide according to any one of claims 1 to 5, wherein the peptide comprises two cationic domains, preferably wherein each cationic domain comprises one of the following sequences: KXKKBKK (SEQ ID NO.1), KXKKBKKXK (SEQ ID NO.2), KBKKBKK (SEQ ID NO.3), KBKKBK (SEQ ID NO.4), KBKK (SEQ ID NO.5), KXKBKXK (SEQID NO.6), KBKXK (SEQ ID NO.7), KBKBK (SEQ ID NO.8), and BKBK (SEQ ID NO.9), more preferably wherein each positive domain consists of one of the following sequences: KXKKBKK(SEQ ID NO.1), KXKKBKKXK(SEQ ID NO.2), KBKKBKK(SEQ ID NO.3), KBKKBK(SEQ ID NO.4), KBKK(SEQ ID NO.5), KXKBKXK(SEQ ID NO.6), KBKXK(SEQ ID NO.7), KBKBK(SEQ ID NO.8), and BKBK (SEQ ID NO.9).

7. A peptide according to any of the preceding claims, wherein the at least one hydrophobic domain comprises hydrophobic amino acid residues, preferably at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% hydrophobic amino acid residues, more preferably the at least one hydrophobic domain consists of hydrophobic amino acid residues.

8. The peptide according to any of the preceding claims, wherein the peptide comprises a hydrophobic domain, preferably wherein the hydrophobic domain comprises one of the following sequences: YQFLI (SEQ ID NO: 10), ILFQY (SEQ ID NO: 11), YRLFI (SEQ ID NO: 12), and FQILY (SEQ ID NO: 13), more preferably wherein the hydrophobic domain consists of one of the following sequences: YQFLI (SEQ ID NO: 10), ILFQY (SEQ ID NO: 11), YRLFI (SEQ ID NO: 12), and FQILY (SEQ ID NO: 13).

9. The peptide according to any one of the preceding claims, wherein the at least one hydrophobic domain is flanked by the at least two cationic domains, preferably wherein the peptide comprises the following structure: [first cationic domain]-[hydrophobic domain]-[second cationic domain], more preferably wherein the peptide consists of the following structure: [First cationic domain]-[hydrophobic domain]-[second cationic domain].

10. The peptide according to any one of the preceding claims, wherein the peptide consists of two cationic domains and one hydrophobic domain.

11. A peptide according to claim 10, wherein the two cationic arm domains consist of a first cationic arm domain and a second cationic arm domain, wherein the first cationic arm domain is selected from the group consisting of: KXKKBKK (SEQ ID NO.1), KXKKBKKXK (SEQ ID NO.2), KBKKBKK (SEQ ID NO.3), KBKKBK (SEQ ID NO.4), and KBKK (SEQID NO.5), and the second cationic arm domain is selected from the group consisting of: KXKBKXK (SEQ ID NO.6), KBKXK (SEQ ID NO.7), KBKBK (SEQ ID NO.8), and BKBK (SEQ ID NO.9).

12. The peptide according to claim 10 or 11, wherein the hydrophobic domain is selected from: YQFLI (SEQ ID NO: 10) or FQILY (SEQ ID NO: 13).

13. A peptide according to any preceding claim, wherein the peptide is less than 35 amino acid residues in length, preferably less than 30 amino acid residues in length, preferably less than 25 amino acid residues in length, preferably less than 20 amino acid residues in length.

14. A peptide according to any preceding claim, wherein the peptide comprises or consists of one of the following sequences: KXKKBKK FQILY KBKXK(ERA5.2)(SEQ ID NO:14) KXKKBKKXK YQFLI KXKBKXK(ERA5.1)(SEQ ID NO:15) KBKKBKK FQILY KBKXK(SEQ ID NO:16) KBKKBKK FQILY KBKBK(ERA 5.3)(SEQ ID NO:17) KBKK YQFLI KBKXK(ERA5.4)(SEQ ID NO:18) KBKKBK FQILY BKBK (ERA5.5) (SEQ ID NO: 19).

15. A conjugate comprising a peptide according to any preceding claim covalently linked to a therapeutic molecule.

16. The conjugate according to claim 15, wherein the peptides are covalently linked via a linker, preferably, the linker is selected from the group consisting of: G, BC, XC, C, GGC, BBC, BXC, XBC, X, XX, B, BB, BX and XB, preferably wherein the linker is C.

17. The conjugate according to claim 15 or 16, wherein the therapeutic molecule is selected from nucleic acids, peptide nucleic acids, antisense oligonucleotides, short interfering RNAs, microRNAs, peptides, cyclic peptides, proteins, drugs and pharmaceuticals, preferably wherein the therapeutic molecule is an antisense oligonucleotide, more preferably wherein the antisense oligonucleotide is a PMO.

18. A pharmaceutical composition comprising the conjugate according to any one of claims 15-17.

19. The conjugate according to any one of claims 15 to 17 or the pharmaceutical composition according to claim 19 for use as a medicament.

20. The conjugate according to any one of claims 15 to 17 or the pharmaceutical composition according to claim 19, for use in the treatment of a disease of the neuromuscular system or the musculoskeletal system, preferably a genetic disease of the neuromuscular system or the musculoskeletal system, more preferably an inherited genetic disease of the neuromuscular system or the musculoskeletal system.